Direxion S&P Biotech Bear 3X

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

CMND

LABU

SBIO

LABD

ARKG

Clearmind Medicine Inc. (CMND) has announced a 1-for-10 reverse stock split effective May 21, 2026, to comply with Nasdaq's minimum bid price requirement. This will reduce its outstanding shares from 10,190,337 to approximately 1,019,033. The company's authorized share capital remains unchanged. Currently, CMND shares are trading at $0.23, down 38.02%.

nasdaq

Clearmind Medicine

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

Nasdaq

Clearmind Medicine Announces 1-for-10 Reverse Stock Split; Stock Down

IBBQ

IDNA

Charles River Laboratories (CRL) shares have declined 18% in the past month, closing at $149.93, despite a 1-year total return of 6.05%. Analysts suggest the stock may be undervalued, with a fair value estimate of $313.61, while a DCF model indicates a lower value of $78.12. Investors are encouraged to weigh these differing perspectives and consider other investment opportunities in the healthcare sector.

Simplywall

Charles River Laboratorie

iShares US Healthcare Providers

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness

INCY

Incyte Stock: Analyst Estimates & Ratings

Barchart Option

Incyte

iShares US Pharma

iShares Global Healthcare

VG Health

Incyte Stock: Analyst Estimates & Ratings

GOVX

GeoVax Labs (NASDAQ:GOVX) stock is down 13.57% in premarket trading after an 80% rally, following the announcement of a $3M private placement, raising concerns over shareholder dilution. The offering includes approximately 2.03 million shares and warrants for an additional 4.05 million shares. Despite the drop, the stock remains above its 20-day and 50-day SMAs, but is significantly below its 100-day and 200-day SMAs, indicating a long-term downtrend.

benzinga_article

GeoVax Labs

Shutterstock

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

Why Is GeoVax Labs Stock Falling Tuesday?

SVRA

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

StockTitan

Savara

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

MEDP

A class action lawsuit has been filed against Medpace Holdings Inc. for securities fraud, alleging misrepresentations regarding cancellation rates and book-to-bill ratios, leading to a 16% stock drop. Investors are urged to act by June 8, 2026, to be appointed as lead plaintiffs. The case is pending in the U.S. District Court for the Southern District of Ohio.

prnewswire

Medpace

SPDR S&P Health Equip

iShares US Medical Devices

Tesla

Teva Pharmaceutical Industries

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

REGN

Levi & Korsinsky is investigating Regeneron Pharmaceuticals (REGN) following significant stock losses after the failure of its Phase 3 melanoma trial of fianlimab + Libtayo. The stock dropped over 10% after the trial did not meet its primary endpoint. Shareholders who suffered losses are encouraged to contact the firm for potential legal recourse.

Regeneron Pharma

18:24 ETRegeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)

Inovio Pharmaceuticals Inc. (INO) shares fell 6.15% to $1.22 on Monday, marking the second consecutive day of losses. The stock is now 59.05% below its 52-week high of $2.98. In contrast, competitors like Johnson & Johnson and Pfizer remained stable, while the overall market showed mixed results with the Dow up 0.32% and NASDAQ down 0.51%. Trading volume was 5.3 million, surpassing the 50-day average of 2.7 million.

MarketWatch Automated

Inovio Pharma

Dow Jones Industrial Average

NASDAQ Composite Index

Johnson & Johnson

Pfizer

Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

IBRX

Rosen Law Firm is reminding investors of ImmunityBio, Inc. (NASDAQ: IBRX) about the May 26, 2026 deadline to lead a securities fraud class action lawsuit. Investors who purchased shares between January 19, 2026, and March 24, 2026, may be eligible for compensation. The lawsuit alleges misleading statements regarding the company's operations. Interested parties can contact the firm for more information.

ImmunityBio

14:56 ETImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

LLYX

Eli Lilly was among the pharmaceutical companies denied certiorari by the Supreme Court, which rejected multiple appeals related to healthcare and commercial cases. This decision diminishes the chances of immediate Supreme Court intervention in these matters. Following the news, Eli Lilly's shares fell by 2.2% to $985.25.

fidelity

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bear 1X Shares

Defiance Daily Target 2X Short LLY ETF

Direxion Daily LLY Bull 2X Shares

Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals

Direxion S&P Biotech Bear 3X(LABD.US)

Clearmind Medicine Announces 1-for-10 Reverse Stock Split; Stock Down

A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness

Incyte Stock: Analyst Estimates & Ratings

Why Is GeoVax Labs Stock Falling Tuesday?

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

18:24 ETRegeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)

Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

14:56 ETImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals